Abstract

The title drug, Ethyl(2S)-2-amino-3-(4{2-amino-6-[(1R)-1-[4-chloro-2-(3-methyl-1H-pyrazol-1-yl) phenyl]-2,2,2-trifluoroethoxy] pyrimidin-4-yl}phenyl)propanoate was reported for carcinoid syndrome diarrhea and approved by FDA in the year 2017. DFT (B3LYP) and Moller-Plesset Second Order (MP2) quantum chemical calculations in the 631G basis set were used to optimize the drug and evaluate the global and local reactivity descriptors. Molecular docking was performed against the tryptophan hydroxylase-1 inhibitor protein to study the binding interactions of the drug with the protein and rationalize the structure-activity relationship. The bond length between drug and protein established the presence of good binding with more interaction or reactivity. Fukui functions were invoked to describe the reactivity and stability of the drug molecule. ADMET profiling of the drug molecule predicts poor solubility and limited absorption in the gastrointestinal tract. BOILED Egg representation displayed low absorption, impermeability to the Blood-Brain barrier, and induced P-gp Substrate. Descriptor parameters were compared between DFT and MP2 optimized structures for each atom, and the most reactive and stable atoms were reported. The current research focuses on the structural and bioactive properties of the title molecule. The study was conducted further to find suitable reactivity centers. This aspect would help to evaluate more reactivity patterns of such types of molecules in future.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call